Targeting PRAME for Acute Myeloid Leukemia Therapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Apr 10

PMID 38596687

Authors

Jinjun Yang

Mengran Chen

Jing Ye

Hongbing Ma

Affiliations

Soon will be listed here.

Abstract

Despite significant progress in targeted therapy for acute myeloid leukemia (AML), clinical outcomes are disappointing for elderly patients, patients with less fit disease characteristics, and patients with adverse disease risk characteristics. Over the past 10 years, adaptive T-cell immunotherapy has been recognized as a strategy for treating various malignant tumors. However, it has faced significant challenges in AML, primarily because myeloid blasts do not contain unique surface antigens. The preferentially expressed antigen in melanoma (PRAME), a cancer-testis antigen, is abnormally expressed in AML and does not exist in normal hematopoietic cells. Accumulating evidence has demonstrated that PRAME is a useful target for treating AML. This paper reviews the structure and function of PRAME, its effects on normal cells and AML blasts, its implications in prognosis and follow-up, and its use in antigen-specific immunotherapy for AML.

Citing Articles

Characterization of a 3S PRAME VLD-Specific T Cell Receptor and Its Use in Investigational Medicinal Products for TCR-T Therapy of Patients with Myeloid Malignancies.

Burdek M, Prinz P, Mutze K, Tippmer S, Geiger C, Longinotti G Cancers (Basel). 2025; 17(2).

PMID: 39858024 PMC: 11763942. DOI: 10.3390/cancers17020242.

In Vivo Induction of Leukemia-Specific Adaptive and Innate Immune Cells by Treatment of AML-Diseased Rats and Therapy-Refractory AML Patients with Blast Modulating Response Modifiers.

Atzler M, Baudrexler T, Amberger D, Rogers N, Rabe A, Schmohl J Int J Mol Sci. 2025; 25(24.

PMID: 39769232 PMC: 11679655. DOI: 10.3390/ijms252413469.

References

Lichtenegger F, Schnorfeil F, Rothe M, Deiser K, Altmann T, Bucklein V . Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial. Clin Transl Immunology. 2020; 9(3):e1117. PMC: 7053229. DOI: 10.1002/cti2.1117. View

Tanaka N, Wang Y, Shiseki M, Takanashi M, Motoji T . Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells. Leuk Res. 2011; 35(9):1219-25. DOI: 10.1016/j.leukres.2011.04.005. View

Rucker F, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik V . Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood. 2019; 134(19):1608-1618. PMC: 9635584. DOI: 10.1182/blood.2019001425. View

Birtle Z, Goodstadt L, Ponting C . Duplication and positive selection among hominin-specific PRAME genes. BMC Genomics. 2005; 6:120. PMC: 1262708. DOI: 10.1186/1471-2164-6-120. View

Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain J, Fenaux P . Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia. 2000; 14(2):324-8. DOI: 10.1038/sj.leu.2401652. View

Greiner J, Goetz M, Schuler P, Bulach C, Hofmann S, Schrezenmeier H . Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody. Br J Haematol. 2022; 198(5):866-874. DOI: 10.1111/bjh.18326. View

Tajeddine N, Millard I, Gailly P, Gala J . Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med. 2006; 44(5):548-55. DOI: 10.1515/CCLM.2006.106. View

Zhang W, Barger C, Eng K, Klinkebiel D, Link P, Omilian A . PRAME expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget. 2016; 7(29):45352-45369. PMC: 5216727. DOI: 10.18632/oncotarget.9977. View

Qin Y, Zhu H, Jiang B, Li J, Lu X, Li L . Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res. 2008; 33(3):384-90. DOI: 10.1016/j.leukres.2008.08.026. View

10.

Floisand Y, Remberger M, Bigalke I, Josefsen D, Valerhaugen H, Inderberg E . WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. Leukemia. 2023; 37(9):1842-1849. DOI: 10.1038/s41375-023-01980-3. View

11.

LaVoy E, Bollard C, Hanley P, Blaney J, OConnor D, Bosch J . A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults. Exerc Immunol Rev. 2015; 21:144-53. View

12.

Hashimoto H, Gungor D, Krickeberg N, Schmitt J, Doll L, Schmidt M . T1 cytokines induce senescence in AML. Leuk Res. 2022; 117:106842. DOI: 10.1016/j.leukres.2022.106842. View

13.

Rezvani K, Yong A, Tawab A, Jafarpour B, Eniafe R, Mielke S . Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood. 2008; 113(10):2245-55. PMC: 2652370. DOI: 10.1182/blood-2008-03-144071. View

14.

Epping M, Wang L, Plumb J, Lieb M, Gronemeyer H, Brown R . A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2007; 104(45):17777-82. PMC: 2077016. DOI: 10.1073/pnas.0702518104. View

15.

Xu Y, Rong L, Meng S, Hou F, Zhang J, Pan G . PRAME promotes in vitro leukemia cells death by regulating S100A4/p53 signaling. Eur Rev Med Pharmacol Sci. 2016; 20(6):1057-63. View

16.

Skou A, Juul-Dam K, Hansen M, Lausen B, Stratmann S, Holmfeldt L . Measurable Residual Disease Monitoring of SPAG6, ST18, PRAME, and XAGE1A Expression in Peripheral Blood May Detect Imminent Relapse in Childhood Acute Myeloid Leukemia. J Mol Diagn. 2021; 23(12):1787-1799. DOI: 10.1016/j.jmoldx.2021.09.004. View

17.

Proto-Siqueira R, Figueiredo-Pontes L, Panepucci R, Garcia A, Rizzatti E, Nascimento F . PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res. 2006; 30(11):1333-9. DOI: 10.1016/j.leukres.2006.02.031. View

18.

Tessari A, Pilla L, Silvia D, Duca M, Paolini B, Carcangiu M . Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?. Breast. 2018; 42:68-73. DOI: 10.1016/j.breast.2018.08.106. View

19.

Lee K, Gowrishankar K, Street J, McGuire H, Luciani F, Hughes B . enrichment of PRAME antigen-specific T cells for adoptive immunotherapy using CD137 activation marker selection. Clin Transl Immunology. 2020; 9(10):e1200. PMC: 7577233. DOI: 10.1002/cti2.1200. View

20.

McEwan P, Scott P, Bishop P, Bella J . Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. J Struct Biol. 2006; 155(2):294-305. DOI: 10.1016/j.jsb.2006.01.016. View